Healthcare Industry News: Ortho-McNeil
News Release - July 14, 2008
Noven Names Joel Lippman, M.D. as Vice President - Clinical Development & Chief Medical OfficerMIAMI--(HSMN NewsFeed)--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN ) today announced the appointment of Joel S. Lippman, M.D. as Vice President – Clinical Development & Chief Medical Officer, effective immediately. In this role, Lippman will lead all aspects of the clinical, regulatory and medical affairs functions at Noven.
Lippman is an obstetrician-gynecologist certified by the American Board of Obstetrics and Gynecology with nearly 20 years of clinical development and medical affairs experience in the pharmaceutical and device industries. Prior to joining Noven, Lippman served Ethicon, Inc., a Johnson & Johnson company, as Worldwide Vice President – Medical Affairs & Chief Medical Officer and as a member of that company’s Global Management Board. Previously, he served Ortho-McNeil Pharmaceutical, Inc., also a Johnson & Johnson company, as Vice President – Clinical Trials. Earlier, he served Wyeth-Ayerst Laboratories in a number of clinical development, medical affairs and related roles.
Lippman holds a Medical Degree from New York Medical College and a Masters in Public Health from Harvard University School of Public Health. He is a Fellow of the American College of Obstetricians and Gynecologists, and is widely published in the areas of menopausal hormone therapy, hormonal contraceptives and other women’s health areas.
“Dr. Lippman’s appointment further expands the industry experience of a Noven team committed to establishing Noven as a high growth specialty pharmaceutical company,” said Peter Brandt, Noven’s President & Chief Executive Officer. “He will direct our clinical, regulatory and medical affairs activities for both our transdermal and oral products, helping design and execute our clinical plans, and leading developmental products through the regulatory process toward commercialization. His experience in the areas of women’s health and central nervous system conditions complements our current areas of therapeutic focus, and his leadership in product selection and development should help us execute on new product opportunities that bring benefit to the company, to our partners and customers, and to the patients who use our products.”
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s business and operations are focused in three principal areas – transdermal drug delivery, the Novogyne joint venture, and its Noven Therapeutics specialty pharmaceutical unit.
Source: Noven Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.